The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESSWIRE / 6, 2025 / Lexaria Bioscience Corp.

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

Get Instant Summarized Text (Gist) Glucagon-like peptide 1 receptor agonists (GLP1RA), used for type 2 diabetes and obesity, are linked to behavioral side effects. An analysis of genetic variants ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...

By increasing the abundance of this one gut microbe in diabetic mice, researchers led by a team at Jiangnan University in China have shown they can "orchestrate the secretion of glucagon-like ...

"Obesity is gradually eroding human health," and the global prevalence of obesity (BMI > 30) is predicted to reach 25 % by 2035, affecting nearly 1.9 billion people. The demand for medications to ...